Owen Mumford is a privately held, family-owned UK medical technology company founded in 1952 and headquartered in Oxfordshire, England, with more than 70 years of innovation in healthcare device development. It pioneered the first plastic autoinjector and specializes in the design and manufacture of drug delivery devices, serving as a trusted partner to many of the world’s largest pharmaceutical, biotech and healthcare organizations. Its portfolio centers on a growing pharmaceutical services business anchored by the next-generation Aidaptus auto-injector platform, alongside an established line of medical devices spanning point-of-care testing, self-injection and pelvic health. Owen Mumford generated approximately GBP 69.4 million of net revenue in its fiscal year 2025 (ended September 30), with roughly 80% of revenue earned in the UK and the U.S.
- 01 Owen Mumford brings a differentiated
- 02 IP-protected drug-delivery platform (Aidaptus) that aligns with embecta’s GLP-1 B2B strategy and gives it a suite of autoinjector
- 03 pen-injector and pen-needle products to offer pharmaceutical partners
- 04 while its chronic-care device portfolio can scale across embecta’s 100-plus-country commercial infrastructure
We are extremely pleased to announce this agreement to acquire Owen Mumford, a company that has earned a global reputation for innovation, quality and patient-centered design. This acquisition is expected to sustainably improve embecta’s revenue growth trajectory and will accelerate our strategic transformation into a broad-based medical supplies company which provides drug delivery platforms to pharmaceutical companies and serves chronic care patients in the obesity, diabetes, autoimmune diseases and anaphylaxis markets.
Owen Mumford has a 70-year track-record of developing innovative solutions with long-term growth potential. With our complementary portfolios and manufacturing expertise, and by leveraging embecta’s commercial scale, we will continue to drive innovation that improves the quality of life for people living with chronic conditions and other healthcare needs while creating new opportunities for our valued customers and the Owen Mumford team.
Dev Kurdikar, Chairman & CEO, Q2 FY2026 earnings call (May 5, 2026): “That financial discipline is what creates the capacity to pursue transactions like Owen Mumford. When we announced this acquisition in March, we noted that Owen Mumford had earned a global reputation for innovation, quality, and patient-centered design. The more time we spend with this team and this business, the more confident we are in that view. At its core, this acquisition accelerates our transformation into a broad-based medical supplies company.” CFO Jake Elguicze added that the deal is expected to be dilutive to adjusted net income in FY2027, immaterial in FY2028 and accretive thereafter, generating a high-single-digit return on invested capital by year four.